Literature DB >> 10927723

Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.

M Bottorff1, P Hansten.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10927723     DOI: 10.1001/archinte.160.15.2273

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


× No keyword cloud information.
  19 in total

Review 1.  A general assessment of the safety of HMG CoA reductase inhibitors (statins).

Authors:  Donald M Black
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 2.  Pharmacologic characteristics of statins.

Authors:  James M McKenney
Journal:  Clin Cardiol       Date:  2003-04       Impact factor: 2.882

3.  Effect of statins on estrogen and androgen levels in postmenopausal women treated with estradiol.

Authors:  A Peck; S Chaikittisilpa; R Mirzaei; J Wang; W J Mack; H N Hodis; F Z Stanczyk
Journal:  Climacteric       Date:  2010-05-07       Impact factor: 3.005

Review 4.  Toxicity of antilipidemic agents: facts and fictions.

Authors:  Antonios M Xydakis; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 5.  Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?

Authors:  Jennifer Martin; Henry Krum
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 7.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Therapy to reduce risk of coronary heart disease.

Authors:  Daniel J Rader
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

Review 9.  Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?

Authors:  Bijesh P Maroo; Carl J Lavie; Richard V Milani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

10.  Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome.

Authors:  David E Slattery; Charles V Pollack
Journal:  West J Emerg Med       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.